BioScrip (BIOS) Rating Increased to Strong-Buy at BidaskClub

BioScrip (NASDAQ:BIOS) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a note issued to investors on Thursday.

Several other equities analysts have also commented on the company. Zacks Investment Research upgraded BioScrip from a “sell” rating to a “hold” rating in a research note on Tuesday, May 15th. SunTrust Banks restated a “buy” rating and set a $3.25 price target on shares of BioScrip in a research note on Thursday, March 8th. Finally, Craig Hallum restated a “buy” rating and set a $3.50 price target on shares of BioScrip in a research note on Thursday, March 8th. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $3.44.

Shares of BioScrip stock opened at $2.93 on Thursday. The company has a debt-to-equity ratio of -4.79, a quick ratio of 1.30 and a current ratio of 1.70. BioScrip has a 12 month low of $1.80 and a 12 month high of $3.39.

BioScrip (NASDAQ:BIOS) last announced its quarterly earnings results on Thursday, May 10th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The firm had revenue of $168.60 million during the quarter, compared to analysts’ expectations of $164.72 million. The company’s revenue for the quarter was down 22.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.18) EPS. equities analysts forecast that BioScrip will post -0.31 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of BIOS. Gotham Asset Management LLC purchased a new position in BioScrip in the fourth quarter valued at about $114,000. MetLife Investment Advisors LLC purchased a new position in BioScrip in the fourth quarter valued at about $174,000. Two Sigma Advisers LP grew its stake in BioScrip by 100.4% in the fourth quarter. Two Sigma Advisers LP now owns 128,245 shares of the company’s stock valued at $373,000 after purchasing an additional 64,238 shares during the last quarter. Wells Fargo & Company MN grew its stake in BioScrip by 34.4% in the fourth quarter. Wells Fargo & Company MN now owns 217,450 shares of the company’s stock valued at $634,000 after purchasing an additional 55,636 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. purchased a new position in BioScrip in the first quarter valued at about $635,000. Institutional investors own 85.46% of the company’s stock.

About BioScrip

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply